Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID
Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas MC, Nath A
Neurology - Neuroimmunology & Neuroinflammation (2022) · n=17
A 17-patient referred case series — 59% with at least one confirmatory neuropathy test, 63% with abnormal skin biopsies, and at least 10 receiving small-fiber neuropathy diagnoses — the pivotal characterisation paper establishing small-fiber neuropathy as a measurable, biopsy-confirmable component of long COVID.
This 2022 Neurology - Neuroimmunology & Neuroinflammation paper from Oaklander and colleagues at Massachusetts General Hospital, the NIH, and Thomas Jefferson University is the pivotal early characterisation of small-fiber neuropathy (SFN) as a measurable, biopsy-confirmable component of long COVID, and the empirical foundation cited in the long-COVID-and-peptides dossier for considering ARA-290 / cibinetide — a peptide whose published Phase II evidence targets the same intraepidermal-nerve-fibre-loss substrate in sarcoid-associated SFN — as a mechanism-bridged intervention candidate. The investigators evaluated 17 referred patients meeting the WHO long-COVID definition with no prior neuropathy history. Mean age was 43.3 years, the cohort was predominantly female and Caucasian, and symptoms reportedly began within one month of acute COVID-19 onset.
The headline findings of the paper, reported in the abstract, are that 59% of evaluated patients had at least one neurodiagnostic test interpretation confirming neuropathy, and that small-fiber neuropathy was the most-prevalent finding — at least 10 of the 17 patients (≥58%) received a small-fiber neuropathy diagnosis. Punch-biopsy assessment of intraepidermal nerve fibre density and related morphology was the principal confirmatory modality, with 63% of patients showing abnormal skin biopsies in the cohort. The authors explicitly framed the pattern as consistent with infection-triggered immune dysregulation as a common underlying mechanism. Treatment in the cohort drew on the immunotherapy approaches used in idiopathic SFN and dysimmune neuropathies — 65% (11 of 17) of patients received corticosteroids and/or intravenous immunoglobulins — with longitudinal symptom improvement averaging 52% across the cohort, though no patient was reported as having achieved complete resolution. The paper's positioning is that small-fiber neuropathy is identifiable in long-COVID patients on the same clinical and neurodiagnostic criteria used for non-COVID SFN, that the biology appears consistent with the dysimmune-neuropathy literature, and that the standard immunomodulatory approaches used elsewhere in SFN produced partial but incomplete benefit in this referred cohort.
This is a referred-patient case series, not a population-based prevalence study and not a randomised trial — the 17 patients were selected by clinical referral for suspected neuropathy and the 59% confirmatory-test-positive figure reports the yield of neurodiagnostic evaluation in patients already suspected of having neuropathic complications, not the prevalence of SFN across long-COVID patients in general. Subsequent population-based and larger referred-cohort series have replicated the basic SFN signal in painful long-COVID phenotypes while reporting prevalence figures that vary widely by referral pattern, time-from-infection window, and definitional threshold; the Oaklander cohort should be read as evidence that SFN is a discrete identifiable component of long COVID rather than as a prevalence estimate. The 17-patient sample is small for any quantitative claim about treatment response — the 52% mean longitudinal improvement figure is uncontrolled (no randomised comparator), is heterogeneous across the cohort (corticosteroids vs IVIG vs combination, with variable dosing), and includes patients receiving other care concurrently; it should not be read as treatment-effect evidence for IVIG or corticosteroids in long-COVID-associated SFN. The pathophysiological mechanism — infection-triggered immune dysregulation producing peripheral nerve-fibre injury — is consistent with the dysimmune neuropathy literature but is not established as the mechanism for the long-COVID cases reported here; small-fiber dysfunction in the setting of dysautonomia, mast-cell activation, or microvascular injury would produce overlapping clinical and biopsy findings. The cibinetide / ARA-290 evidence cited as a mechanism bridge is in sarcoid-associated SFN and diabetic peripheral neuropathy (Heij et al. 2012, Brines et al. 2015, Culver et al. 2017) — not in long-COVID-associated SFN, in which no cibinetide trial has been conducted; the bridge is mechanistically credible and clinically untested.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.